BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IMV102 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IMV102\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07802756-3293@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:IMV102: Phase 1 readout est. (NCT07802756)
DESCRIPTION:IMV102\, phase 1.\nStudy: Dose-Escalation/Expansion Study of iM
 agic in Relapsed/Refractory Hematologic Malignancies\nEstimated primary co
 mpletion: 10 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/imv102#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07802756
URL:https://assetmemo.bio/drug/imv102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493135-3293@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:IMV102: Phase 1 readout est. (NCT07493135)
DESCRIPTION:IMV102\, phase 1\, Multiple Myeloma.\nStudy: A Study of IMV102 
 in Patients With Relapsed/Refractory Multiple Myeloma\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/imv102#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07493135
URL:https://assetmemo.bio/drug/imv102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
